Esperion Supports Collaborative Study with an Integrated and Learning Health Care Delivery System in Northern California to Study the Effects of NEXLIZET® (bempedoic acid and ezetimibe) in Reducing LDL-Cholesterol Following a Recent Acute Coronary Syndrome Event
April 25, 2022 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 25, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced support for a study to evaluate the effects of bempedoic acid and ezetimibe (NEXLIZET) on short-term...
Esperion Announces Commercial Availability of NEXLIZET™ (bempedoic acid and ezetimibe) Tablets and Ushers in New Era of Oral Combination Medicine for LDL-Cholesterol Lowering
June 04, 2020 07:00 ET
|
Esperion Therapeutics, Inc.
– First-Ever Non-Statin Combination Medicine, Providing 38 Percent Mean LDL-C Lowering – – Esperion Aims to Set New Industry Standard by Pricing NEXLIZET for Patient Affordability and Access with...
Esperion to Participate in Fireside Chat at the BofA Securities 2020 Healthcare Conference
May 07, 2020 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 07, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside...
Esperion Reports First Quarter 2020 Financial Results and Provides Company Update
May 06, 2020 16:05 ET
|
Esperion Therapeutics, Inc.
Company Secures Marketing Approvals for NEXLETOL™ and NEXLIZET™ Tablets in the U.S. as well as for NILEMDO™ and NUSTENDI™ Tablets in EuropeNEXLETOL™ (bempedoic acid) Tablets Commercially Available in...
Esperion to Report First Quarter 2020 Financial Results May 6, 2020
April 30, 2020 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 30, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2020 financial results after the close of the U.S. financial markets on May...
Esperion Announces Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of NEXLETOL™ (bempedoic acid) and NEXLIZET™ (bempedoic acid and ezetimibe) Tablets in Japan
April 20, 2020 07:00 ET
|
Esperion Therapeutics, Inc.
– Esperion to Receive $60 Million Upfront Payment – – Up to $510 Million in Total Milestones – – Substantial Tiered Royalties – – Combines Esperion’s Expertise in Lipid Management with...
Esperion Announces European Commission Approval of the NUSTENDI™ (bempedoic acid and ezetimibe) Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
April 06, 2020 07:05 ET
|
Esperion Therapeutics, Inc.
– First Non-Statin, LDL-C Lowering Combination Medicine Ever Approved in Europe – – NUSTENDI Is Approved for Patients Who Require Additional LDL-Cholesterol Lowering on a Background Statin, Other...
Esperion Announces European Commission Approval of the NILEMDO™ (bempedoic acid) Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
April 06, 2020 07:00 ET
|
Esperion Therapeutics, Inc.
– First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine Approved in Europe in Almost Two Decades for Indicated Patients – – NILEMDO Is Approved for Patients Who Require Additional...